resisttb
- May 10
- 1 min read

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend patent on lifesaving

Doctors Without Borders/Médecins Sans Frontières (MSF) applauds today’s news that the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the tuberculosis (TB) drug bedaquiline beyond when its primary patent expires in July. The rejection is a significant step toward increasing access to the lifesaving TB drug. Read more here.

Recent Posts

See All

endTB Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

Clinical trial results presented for the first time at the Union World Conference on Lung Health revealed evidence to support the use of four new, improved regimens to treat multi-drug resistant tuber

New preventive treatment for children cuts the risk of drug-resistant tuberculosis by more than half

Clinical trial results presented in Paris at the Union World Conference on Lung Health showed that a once-daily dose of a widely available antibiotic over six months cut a child’s risk of developing m

Ending TB Is Within Reach — So Why Are Millions Still Dying?

Tuberculosis, which is preventable and curable, has reclaimed the title of the world’s leading infectious disease killer, after being supplanted from its long reign by Covid-19. But worldwide, 40 perc